Market Access
Gain high value access and increase the profitability of your brands
SOLUTIONS
-
Life Sciences Solutions
-
Healthcare Solutions
-
Medical Device and Diagnostic
-
U.S. Government
Life Sciences Solutions
Bringing together unparalleled healthcare data, advanced analytics, innovative technologies, and healthcare expertise to create intelligent connections that speed the development and commercialization of innovative medicines to improve patient lives.
Learn MoreLife Sciences Solutions
Healthcare Solutions
Accelerate digital innovation to enable smarter decisions that reduce cost, modernize patient and consumer engagement, and improve health outcomes.
Learn MoreHealthcare Solutions
Medical Device and Diagnostic Solutions
Your world is unique – and quite different from pharma. In the U.S., decision-making has shifted from individual physicians to integrated networks--GPOs, IDNs and payers. These groups have heightened the focus on proving your solution’s value, demanding outcomes analyses and putting pressure on pricing.
Learn MoreMedical Device and Diagnostic Solutions
U.S. Government Solutions
For government agencies and organizations at every level—from federal or national to regional and local—Big Data can have a huge impact on public health.
Learn MoreU.S. Government Solutions
U.S. PROGRESS POINT
A curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the United States healthcare market.
LEARN MOREU.S. BLOGS
Get the latest insights on our life sciences, healthcare, and medical technology solutions in the United States. Follow our blog today!
LEARN MOREWhite Paper
The 340B Drug Discount Program Exceeds $100B in 2022
Apr 14, 2023
This article is the latest in IQVIA's series of yearly reports on the size and growth of the 340B drug discount program. In 2022, 340B sales exceeded $100B in WAC dollars for the first time despite contract pharmacy restrictions imposed by manufacturers. Looking forward, 340B growth is likely to be influenced by continued developments in contract pharmacy restrictions and related court cases, the impact of the Inflation Reduction Act, recent changes in pricing strategies in the insulin market, and the possibility of expansion of the 340B patient definition. Download this white paper to learn more.
Related solutions
Market Access Strategy Consulting
Rely on market-leading strategists to help you achieve maximum access and profitability